BlossomHill Therapeutics, Inc.
BlossomHill Therapeutics is a clinical-stage biotech developing small molecule drugs for oncology and autoimmune diseases, with $257M in total funding. The company has raised a Series B and employs 70 people.
The growth story
BlossomHill Therapeutics, Inc. grew from 9 to 70 employees between 2021 and 2026, raising $257M along the way, most recently a Series B in December 2025.
About
BlossomHill Therapeutics focuses on small molecule drug discovery for cancer and autoimmune conditions where existing treatments are inadequate. The company was co-founded by a drug development scientist and biotech executive.
The company has raised $257M, including a recent Series B, suggesting strong investor interest in its pipeline. With 70 employees, it operates at a scale typical for clinical-stage biotechs.
Founders and leadership
Research is the largest function, with 7 employees. The company was co-founded by J. Jean Cui, a drug design expert, and Y. Peter Li, who brings business experience.
The BlossomHill Therapeutics, Inc. org chart
J. Jean Cui (Scientific Founder, President and CEO) leads 41 mapped leaders with 14 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 21 (+5% YoY), Business Development 9 (+29% YoY), Quality Assurance 4 (+33% YoY), Healthcare Services 4 (+33% YoY), Legal 4 (+33% YoY), Accounting 3 (+200% YoY).
Talent flow
The team draws heavily from Pfizer (13 hires) and Turning Point Therapeutics (12 hires). Alumni have moved to roles at Zai Lab, Avenzo Therapeutics, and other biotechs.
Most common previous employers of BlossomHill Therapeutics, Inc. staff: Pfizer (13), Turning Point Therapeutics (12), Amgen (6), Arena Pharmaceuticals (6), Takeda (4), Bristol Myers Squibb (4). Former BlossomHill Therapeutics, Inc. employees most often moved to Plaisance Capital Management (1), Zai Lab (1), Avenzo Therapeutics (1), Neurocrine Biosciences (1), Regor (1), Vividion Therapeutics (1).
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at BlossomHill Therapeutics, Inc.: Biotechnology (27), Pharmaceutics (23), Drug Development (20), Drug Discovery (18), Oncology (18), Clinical Trials (17), Life Sciences (17), Good Clinical Practice (GCP) (14).
Where the team actually sits
BlossomHill Therapeutics, Inc. people are concentrated in California, United States (38), Greater Boston (2), Massachusetts, United States (2), United States (2).
Search footprint
BlossomHill Therapeutics, Inc. attracts about 733 organic search visits a month, traffic worth roughly $2K a month if bought through ads. It gained 20 ranking keywords and lost 23 in the last period.
Frequently asked
BlossomHill Therapeutics, Inc. has 70 employees as of September 2026.
BlossomHill Therapeutics, Inc. has raised $257M in total, most recently a Series B round in December 2025.
BlossomHill Therapeutics, Inc. was founded in 2020 by J. Jean Cui, Yishan (Peter) Li.
J. Jean Cui (Scientific Founder, President and CEO) sits at the top of BlossomHill Therapeutics, Inc.'s reporting structure, with 14 direct reports.
The most common previous employers of current BlossomHill Therapeutics, Inc. staff are Pfizer (13 people), Turning Point Therapeutics (12 people), Amgen (6 people).
Former BlossomHill Therapeutics, Inc. employees most often move to Plaisance Capital Management (1), Zai Lab (1), Avenzo Therapeutics (1).
BlossomHill Therapeutics, Inc. attracts about 733 organic search visits a month, worth roughly $2K a month in equivalent ad spend.
The most common skills among BlossomHill Therapeutics, Inc. staff are Biotechnology, Pharmaceutics, Drug Development, Drug Discovery, Oncology.
BlossomHill Therapeutics, Inc. staff are concentrated in California, United States (38), Greater Boston (2), Massachusetts, United States (2).
BlossomHill Therapeutics, Inc. has about 21 people in Research, up 5% over the past year, as of September 2026.
BlossomHill Therapeutics, Inc. has about 9 people in Business Development, up 29% over the past year, as of September 2026.
Computed from 54 current and 10 former BlossomHill Therapeutics, Inc. profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.